Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | MTOR | P42345 | 1/20 | 0.59 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.59 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.59 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.49 |
| ▸ | ST6GAL1 | P15907 | 4/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16976494 | 0.92 | LMNA (0.58) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL23613719 | 0.91 | LMNA (0.57) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL12590134 | 0.91 | LMNA (0.62) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL12015200 | 0.91 | LMNA (0.62) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL24264156 | 0.91 | LMNA (0.62) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL12087522 | 0.91 | LMNA (0.62) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL7137839 | 0.90 | LMNA (0.56) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL16359972 | 0.90 | LMNA (0.74) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL13134586 | 0.90 | LMNA (0.60) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL23880680 | 0.90 | LMNA (0.74) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232798-A1 | Process For The Synthesis Of 2'-O-Substituted Pyrimidines And Oligomeric Compounds Therefrom | COOK PHILLIP D | 2007-10-04 | — | — | US | claimed |
| US-11542505-B1 | Substituted RIG-I agonists: compositions and methods thereof | MERCK SHARP & DOHME LLC (US) | 2023-01-03 | — | — | US | disclosed |
| EP-2928876-B1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | MERCK SHARP & DOHME (US) | 2018-01-17 | — | — | EP | disclosed |
| US-9624249-B2 | Nucleoside kinase bypass compositions and methods | MERCK SHARP & DOHME CORP. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20150315221-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | MERCK SHARP & DOHME CORP. (US) | 2015-11-05 | — | — | US | disclosed |
| WO-2014088923-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315221-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | DCK, DTYMK, TK1 | LMNA 4073/4885THRB 2923/4885MTOR 758/4885 |
| US-11542505-B1 | Substituted RIG-I agonists: compositions and methods thereof | MAVS, TLR3, DDX18 | LMNA 2612/4885THRB 2068/4885MTOR 4059/4885 |
| US-20070232798-A1 | Process For The Synthesis Of 2'-O-Substituted Pyrimidines And Oligomeric Compounds Therefrom | TYMS, RRM2, ATIC | LMNA 3653/4885THRB 3385/4885MTOR 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.